News

Case study notes challenges to CAD diagnosis, care in Pakistan

Researchers said a case of cold agglutinin disease (CAD) in a 92-year-old man in Pakistan illustrates the challenges of CAD diagnosis and management in developing countries. The man’s experience highlights “the urgent need to improve healthcare infrastructure and enhance diagnostic capabilities while facilitating equitable access to essential CAD treatments…

Trial results for novel CAD treatment now expected early 2025

The results from Annexon Biosciences‘ ongoing proof-of-concept clinical trial of ANX1502, its novel treatment candidate for cold agglutinin disease (CAD), are now expected in early 2025, the company has announced. That trial is testing a new tablet formulation of the oral therapy in people with CAD. Earlier this…

Rituximab treatment resolves serious case of secondary CAD

Treatment with rituximab — commonly used off-label for cold agglutinin disease (CAD) — was reported to successfully resolve a serious case of CAD secondary to an Epstein-Barr virus (EBV) infection and potential contraceptive pill toxicity in a young woman in Europe. The woman had developed severe jaundice and liver…

Review study highlights challenges in CAD treatment, diagnosis

Establishing a diagnosis of autoimmune hemolytic anemia (AIHA), a group of conditions including cold agglutinin disease (CAD), is sometimes difficult, due to the high variability in signs and symptoms and the possibility of a secondary cause, a review study showed. “Additionally, therapy is poorly evidence-based and mainly funded on…

AI model helps identify medications to repurpose for rare diseases

Researchers have developed an artificial intelligence (AI)-based model designed to identify existing medicines that could be repurposed to treat rare conditions such as cold agglutinin disease (CAD). The model, called TxGNN, was able to identify possible therapeutic candidates for more than 17,000 conditions in a study, and researchers believe…